0 Yorumlar
0 hisse senetleri
154 Views
0 önizleme
Site içinde arama yapın
Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek
-
Please log in to like, share and comment!
-
Monoclonal Antibodies Market Insights: Growth, Share, Value, Size, and Analysis" Global Monoclonal Antibodies Market Size, Share, and Trends Analysis Report—Industry Overview and Forecast to 2032 Executive Summary: Global monoclonal antibodies market size was valued at USD 263.22 billion in 2024 and is projected to reach USD 719.81 billion by 2032, with a CAGR of 13.40% during the forecast period of 2025 to 2032. Global Monoclonal Antibodies...0 Yorumlar 0 hisse senetleri 173 Views 0 önizleme
-
Monoclonal Antibodies Market Opportunities, Industry Statistics, Trends, Revenue Analysis"Executive Summary: Global monoclonal antibodies market size was valued at USD 263.22 billion in 2024 and is projected to reach USD 719.81 billion by 2032, with a CAGR of 13.40% during the forecast period of 2025 to 2032. The Monoclonal Antibodies Market is experiencing unprecedented growth driven by rapid technological advancements, evolving consumer preferences, and...0 Yorumlar 0 hisse senetleri 105 Views 0 önizleme
-
EGFR Inhibitors Market Advances with Growing Applications in Targeted Cancer Therapies"Global Epidermal Growth Factor Receptor Inhibitors Market Size, Share, and Trends Analysis Report—Industry Overview and Forecast to 2032 Executive Summary: The global epidermal growth factor receptor inhibitors market size was valued at USD 14.10 billion in 2024 and is projected to reach USD 28.10 billion by 2032, with a CAGR of 9.00% during the forecast period of 2025 to 2032....0 Yorumlar 0 hisse senetleri 131 Views 0 önizleme
-
EGFR Inhibitors Market Strengthens Amid Rising Cancer Incidence and Breakthrough Targeted Therapies"Epidermal Growth Factor Receptor Inhibitors Market Size, Share, and Trends Analysis Report—Industry Overview and Forecast to 2032 According to Data Bridge Market Research firms, the EGFR Targeted Therapies is set to achieve robust growth, supported by emerging economies and digital transformation. Companies operating in the Cancer Growth Receptor Blockers are leveraging...0 Yorumlar 0 hisse senetleri 255 Views 0 önizleme
-
PCSK9 Inhibitors Market Driven by Cardiovascular Disease PrevalencePCSK9 inhibitors are a class of lipid-lowering biologics designed to target proprotein convertase subtilisin/kexin type 9, offering a potent reduction in low-density lipoprotein (LDL) cholesterol for patients at high cardiovascular risk. Administered via subcutaneous injection, these monoclonal antibodies and small molecules block PCSK9 interaction with LDL receptors, enhancing receptor...0 Yorumlar 0 hisse senetleri 229 Views 0 önizleme